< Back to previous page
Researcher
Peter Carmeliet
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Cardiac and vascular medicine
- See also: Peter Carmeliet (Flanders Institute for Biotechnology)
Affiliations
- Laboratory of Angiogenesis and Vascular Metabolism (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2012 → Today - Carmeliet Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Angiogenesis and Vascular Metabolism (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → Today - Centre for Molecular and Vascular Biology (Division)
Member
From1 Oct 1999 → 30 Sep 2005
Projects
1 - 10 of 110
- Angiogenesis and Vascular HeterogeneityFrom9 Jan 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Immunomodulatory role of graft endothelial cells to improve organ transplantationFrom30 Nov 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Demystifying the mystery genome for alternative immunotherapy targets: combining artificial intelligence-based discovery of immunomodulatory endothelial cell targets and in vivo target validation.From1 Oct 2022 → 30 Sep 2023Funding: BOF - postdoctoral mandates
- DEMYSTIFYING ALTERNATIVE IMMUNOTHERAPY MYSTERY TARGETS BY COMBINING ARTIFICIAL INTELLIGENCE- BASED TARGET DISCOVERY AND LARGER-SCALE TARGET VALIDATIONFrom1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Immunomodulatory endothelial cells (IMECs): dissecting their immunosuppressive / im- munostimulatory features via nanoparticle-based gene silencing or overexpressionFrom26 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Validating novel AI-predicted targets for alternative cancer immunotherapyFrom20 Sep 2022 → TodayFunding: FWO fellowships, Foundations, funds and other with scientific goal
- Angiogenesis and Vascular HeterogeneityFrom19 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Metabolic and epigenetic interplay in neural progenitor cells: investigating neurodevelopmental disorders associated with impaired neural progenitor cell expansion (MEPIcephaly).From1 Jun 2022 → TodayFunding: FWO research project (including WEAVE projects)
- Imaging the invisible in preclinical models using magnetic particle imagingFrom1 May 2022 → TodayFunding: FWO Large scale research infrastructure
- Next-generation, multi-technology immune-monitoring and easy-access spectral flow cytometryFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
Publications
521 - 530 of 587
- Oxygen-Induced Retinopathy in Mice: Amplification by Neonatal IGF-I Deficit and Attenuation by IGF-I Administration(2009)
Authors: Sophie Vanhaesebrouck, Lieve Moons, Christine Vanhole, Peter Carmeliet, Francis de Zegher
Pages: 307 - 310 - Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited(2009)
Authors: Max Mazzone, Peter Carmeliet
Pages: 167 - 170 - Genetic Insights and Therapeutic Potential of the Neuro-Vascular Link: Consequences for Tissue Regeneration(2009)
Authors: Peter Carmeliet
Pages: 677 - 677 - Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization(2009)
Authors: Max Mazzone, Rodrigo Leite-de-Oliveira, Frederik De Smet, Koen Debackere, Aernout Luttun, Peter Carmeliet
Pages: 839 - 851 - Vascular Endothelial Growth Factor-B Induces Myocardium-Specific Angiogenesis and Arteriogenesis via Vascular Endothelial Growth Factor Receptor-1-and Neuropilin Receptor-1-Dependent Mechanisms(2009)
Authors: Peter Carmeliet
Pages: 845 - Loss of the Cholesterol-Binding Protein Prominin-1/CD133 Causes Disk Dysmorphogenesis and Photoreceptor Degeneration(2009)
Authors: Mieke Dewerchin, Lieve Moons, Peter Carmeliet
Pages: 2297 - 2308 - Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration(2009)
Authors: Ludo Van Den Bosch, Annelies Van Hoecke, Peter Carmeliet, Patrik Verstreken, Wim Robberecht
Pages: 472 - 481 - Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease(2009)
Authors: Peter Carmeliet
Pages: 139 - 152 - Antibiotics may impair hematopoietic recovery after cytotoxic myeloablation(2009)
Authors: Marc Tjwa, Lieve Moons, Catherine Verfaillie, Peter Carmeliet
Pages: 1608 - 1609 - Regulation of Angiogenesis by Oxygen and Metabolism(2009)
Authors: Max Mazzone, Peter Carmeliet
Pages: 167 - 179
Patents
1 - 10 of 10
- Carnitine palmitoyltransferase 1 inhibitors for inhibition of pathological angiogenesis (Inventor)
- Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor (Inventor)
- Inhibition of plgf to treat philadelphia chromosome positive leukemia (Inventor)
- Means and methods for treating lung hypoplasia (Inventor)
- Use of VEGF and homologues to treat neuron disorders (Inventor)
- Novel anti-PLGF antibody (Inventor)
- Anti-angiogenic therapy (Inventor)
- Responsiveness to angiogenesis inhibitors (Inventor)
- GLUTAMINE SYNTHETASE INHIBITORS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS (Inventor)
- CARNITINE PALMITOYLTRANSFERASE 1 INHIBITORS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS (Inventor)